3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Wilms Tumor
1
Uveal Melanoma
1
Thyroid Cancer, Papillary
1
Sarcoma, Ewing
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Medulloblastoma
1
Glioma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Interventions
Temozolomide
6
Radiotherapy
4
Irinotecan
3
lutetium Lu 177 dotatate
2
Nivolumab
2
Carboplatin
2
sonidegib
1
sodium thiosulfate
1
silmitasertib
1
poly ICLC
1
plerixafor
1
olaparib
1
gallium Ga 68 dotatate
1
etoposide phosphate
1
entrectinib
1
dinutuximab
1
bempegaldesleukin
1
adavosertib
1
abemaciclib
1
Vincristine
1
Vascular Endothelial Growth Factor A
1
Vaccines
1
Triiodothyronine
1
TPI-287
1
Surgical Procedures, Operative
1
Radiation
1
Peripheral Blood Stem Cell Transplantation
1
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
1
Microarray Analysis
1
Melphalan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Medulloblastoma
×
entrectinib
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA